Sep 11, 2025
YolTech Therapeutics Raises $45 Million in Series B Financing Led by AstraZeneca-CICC
Apr 28, 2025
YolTech Announces First Clinical Data from Ongoing Investigator-Initiated Trial of YOLT-101, An In-Vivo Base Editing Therapy for Familial Hypercholesterolemia
Feb 25, 2025
YolTech Therapeutics Announces Positive Clinical Data for YOLT-203, an In Vivo Gene Editing Therapy for Primary Hyperoxaluria Type 1 (PH1)
Jan 20, 2025
YolTech Therapeutics to Initiate a Clinical Trial for YOLT-204, a First-in-Class Bone Marrow-Targeted In Vivo Gene Editing Therapy for b-Thalassemia
Dec 21, 2024
YolTech Therapeutics Announces Successful Completion of Dose Escalation Phase in Phase I Trial of YOLT-201 for ATTR
Sep 04, 2024
/C O R R E C T I O N -- YolTech Therapeutics/
Sep 04, 2024
YolTech Therapeutics Receives U.S. FDA Rare Pediatric Disease Designation for YOLT-203 in Treating Primary Hyperoxaluria Type 1
Aug 22, 2024
YolTech Therapeutics Administers First Patient Dose in IIT of YOLT-203, the World's First In Vivo Gene Editing Therapy for PH1
Jul 11, 2024
First Patient Dosed in Phase I Clinical Trial of YOLT-201
Jun 18, 2024
YolTech and KACTUS Join Forces to Propel Innovative DNA editing system in Greater China
Apr 02, 2024
First Patient Dosed in Clinical Trial of YOLT-101 for the Treatment of FH
Mar 27, 2024
YolTech Therapeutics to Participate in 2024 Cell & Gene Meeting on the Mediterranean
Mar 13, 2024
YolTech Therapeutics to Showcase Breakthroughs in in vivo Gene Editing at TIDES Asia 2024
Mar 04, 2024
Landmark Clinical Approval for YOLT-201 Obtained by the NMPA
Jan 02, 2024
YolTech Therapeutics to Present and Unveil Major Progress at Biotech Showcase 2024